|
Segment Information Segment Information (Details) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Sep. 30, 2012
|
Jun. 30, 2012
|
Mar. 31, 2012
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|
| Segment Reporting Information [Line Items] | |||||||||||
| Depreciation and amortization | $ 1,445.6 | $ 1,462.2 | $ 1,373.6 | ||||||||
| Revenue | 5,808.8 | 5,772.6 | 5,929.7 | 5,602.0 | 5,957.3 | 5,443.3 | 5,600.7 | 5,602.0 | 23,113.1 | 22,603.4 | 24,286.5 |
| Long-Lived Assets | 8,741.3 | 8,990.5 | 8,741.3 | 8,990.5 | 9,372.4 | ||||||
| Asset impairment, restructuring, and other special charges | (35.4) | 0 | (63.5) | (21.7) | (204.0) | (53.3) | 0 | (23.8) | (120.6) | (281.1) | (401.4) |
| Income before income taxes | 909.9 | 1,513.4 | 1,514.9 | 1,951.1 | 1,012.4 | 1,874.7 | 1,185.7 | 1,335.3 | 5,889.3 | 5,408.2 | 5,349.5 |
| Acquired in-process research and development | (57.1) | 0 | 0 | 0 | (57.1) | 0 | (388.0) | ||||
| Gain (Loss) on Contract Termination | 495.4 | 787.8 | 0 | ||||||||
|
Accounts Receivable, Minimum [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Concentration Risk, Percentage | 9.00% | 9.00% | 9.00% | ||||||||
|
Accounts Receivable, Maximum [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Concentration Risk, Percentage | 18.00% | 18.00% | 18.00% | ||||||||
|
Customer Concentration Risk, Minimum [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Concentration Risk, Percentage | 10.00% | 10.00% | 10.00% | ||||||||
|
Customer Concentration Risk, Maximum [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Concentration Risk, Percentage | 19.00% | 19.00% | 19.00% | ||||||||
|
United States [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 12,889.7 | 12,313.1 | 12,977.2 | ||||||||
| Long-Lived Assets | 4,649.6 | 5,064.7 | 4,649.6 | 5,064.7 | 5,485.3 | ||||||
|
Europe [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 4,338.4 | 4,259.7 | 5,290.9 | ||||||||
| Long-Lived Assets | 2,469.7 | 2,281.1 | 2,469.7 | 2,281.1 | 2,220.2 | ||||||
|
Japan [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 2,063.8 | 2,246.2 | 2,104.1 | ||||||||
| Long-Lived Assets | 81.1 | 101.5 | 81.1 | 101.5 | 102.9 | ||||||
|
Other Foreign Countries [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 3,821.2 | 3,784.4 | 3,914.3 | ||||||||
| Long-Lived Assets | 1,540.9 | 1,543.2 | 1,540.9 | 1,543.2 | 1,564.0 | ||||||
|
Total segment [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Income before income taxes | 5,571.6 | 4,901.5 | 6,138.9 | ||||||||
|
Endocrinology [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 7,304.4 | 6,810.9 | 6,806.7 | ||||||||
|
Neuroscience [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 7,216.2 | 7,575.1 | 9,723.8 | ||||||||
|
Oncology [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 3,268.5 | 3,281.6 | 3,322.2 | ||||||||
|
Cardiovascular [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 2,923.2 | 2,632.5 | 2,486.4 | ||||||||
|
Other Pharmaceuticals [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 249.3 | 266.8 | 268.8 | ||||||||
|
Pharmaceutical Products Total [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 20,961.6 | 20,566.9 | 22,607.9 | ||||||||
| Income before income taxes | 5,015.0 | 4,393.4 | 5,837.9 | ||||||||
|
Animal Health Products [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | 2,151.5 | 2,036.5 | 1,678.6 | ||||||||
| Income before income taxes | 556.6 | 508.1 | 301.0 | ||||||||
|
Human Pharmaceutical Products [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Depreciation and amortization | 1,350.0 | 1,370.0 | 1,300.0 | ||||||||
|
Amylin [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Gain (Loss) on Contract Termination | 495.4 | 787.8 | 0 | ||||||||
|
Animal Health Products [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Depreciation and amortization | 99.4 | 91.1 | 78.1 | ||||||||
|
Cymbalta [Member] | United States [Member]
|
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||
| Revenue | $ 3,960.0 | ||||||||||